| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1845* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 487* | 2021 |
| Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large … M Bukhari, M Lunt, BJ Harrison, DGI Scott, DPM Symmons, AJ Silman Arthritis & Rheumatism: Official Journal of the American College of …, 2002 | 293 | 2002 |
| BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies T Ding, J Ledingham, R Luqmani, S Westlake, K Hyrich, M Lunt, P Kiely, ... Rheumatology 49 (11), 2217-2219, 2010 | 251 | 2010 |
| British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis SL Mackie, C Dejaco, S Appenzeller, D Camellino, C Duftner, ... Rheumatology 59 (3), e1-e23, 2020 | 240 | 2020 |
| Influence of disease‐modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study MAS Bukhari, NJ Wiles, M Lunt, BJ Harrison, DGI Scott, DPM Symmons, ... Arthritis & Rheumatism 48 (1), 46-53, 2003 | 226 | 2003 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
| Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis LK Mercer, M Lunt, ALS Low, WG Dixon, KD Watson, DPM Symmons, ... Annals of the rheumatic diseases 74 (6), 1087-1093, 2015 | 190 | 2015 |
| Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid MJ Bottomley, NJA Webb, CJ Watson, L Holt, M Bukhari, J Denton, ... Clinical & Experimental Immunology 119 (1), 182-188, 2000 | 174 | 2000 |
| The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis CR Holroyd, R Seth, M Bukhari, A Malaviya, C Holmes, E Curtis, C Chan, ... Rheumatology 58 (2), e3-e42, 2019 | 156 | 2019 |
| Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy M Bukhari, S Hollis, T Moore, MIV Jayson, AL Herrick Rheumatology 39 (5), 506-512, 2000 | 139 | 2000 |
| The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk … M Bukhari, W Thomson, H Naseem, D Bunn, A Silman, D Symmons, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 138 | 2007 |
| Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community‐based study M Bukhari, B Harrison, M Lunt, DGI Scott, DPM Symmons, AJ Silman Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 137 | 2001 |
| Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer … S Toback, E Galiza, C Cosgrove, J Galloway, AL Goodman, PA Swift, ... The Lancet Respiratory Medicine 10 (2), 167-179, 2022 | 135 | 2022 |
| Alkaptonuria JB Mistry, M Bukhari, AM Taylor Rare Diseases 1 (1), e27475, 2013 | 126 | 2013 |
| Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease … NJ Wiles, M Lunt, EM Barrett, M Bukhari, AJ Silman, DPM Symmons, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 125 | 2001 |
| Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease … NJ Wiles, M Lunt, EM Barrett, M Bukhari, AJ Silman, DPM Symmons, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 125 | 2001 |
| Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis LK Mercer, JB Galloway, M Lunt, R Davies, ALS Low, WG Dixon, ... Annals of the rheumatic diseases 76 (3), 497-503, 2017 | 119 | 2017 |
| Clinical utility of random anti–tumor necrosis factor drug–level testing and measurement of antidrug antibodies on the long‐term treatment response in rheumatoid arthritis M Jani, H Chinoy, RB Warren, CEM Griffiths, D Plant, B Fu, AW Morgan, ... Arthritis & rheumatology 67 (8), 2011-2019, 2015 | 111 | 2015 |
| Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis M Bukhari, AL Herrick, T Moore, J Manning, MIV Jayson Rheumatology 35 (11), 1127-1131, 1995 | 99 | 1995 |
